Invention Grant
- Patent Title: Eliminating MHC restriction from the T cell receptor as a strategy for immunotherapy
-
Application No.: US16177740Application Date: 2018-11-01
-
Publication No.: US11299552B2Publication Date: 2022-04-12
- Inventor: Thomas Yankee , John Szarejko
- Applicant: University of Kansas
- Applicant Address: US KS Lawrence
- Assignee: University of Kansas
- Current Assignee: University of Kansas
- Current Assignee Address: US KS Lawrence
- Agency: Foley & Lardner LLP
- Main IPC: C07K16/30
- IPC: C07K16/30 ; A61K39/39 ; C07K14/705 ; C07K16/28 ; C07K14/725 ; C07K16/00 ; A61K38/17 ; C07K14/495 ; C07K14/65 ; C12N15/113 ; C12N15/62 ; A61K38/10

Abstract:
The present disclosure generally relates to chimeric antigen receptors, more specifically to chimeric antigen receptor compositions and methods for use of the same. The present disclosure also provides for nucleic acid molecules and expression vectors for making and using the chimeric antigen receptors and for co-receptor signaling using such chimeric antigen receptors. The present disclosure also provides methods of treatment using such compositions. The chimeric antigen receptors of the present disclosure interact with the endogenous T-cell receptor complex enabling physiological control of signaling and T-cell response and can be combined with ligands such as co-stimulatory ligands for further controlling and influencing T-cell activation and response.
Public/Granted literature
- US20190055318A1 ELIMINATING MHC RESTRICTION FROM THE T CELL RECEPTOR AS A STRATEGY FOR IMMUNOTHERAPY Public/Granted day:2019-02-21
Information query